Author(s) :

Paul, Monica, Ioana, Florina, Monica, Ana-Maria .

Volume/Issue :

Abstract :

Monitoring disease progression and adjusting treatment based on biomarkers is essential in oncology. Circulating tumor DNA (ctDNA) is an emerging biomarker used for early detection of recurrence and monitoring response to treatment, while the neutrophil/lymphocyte ratio (NLR) is a recognized inflammatory marker for oncological prognosis. The aim of this study was to report two clinical cases and to assess the efficiency of ctDNA and NLR in guiding oncological treatments. Two clinical cases were analyzed: for one patient with colon cancer, five comparative determinations of ctDNA and NLR were performed, while for a patient with gastric cancer, three such determinations were performed. Both methods were compared in terms of sensitivity and correlation with patients' clinical course. The findings indicated that for the patient with colon cancer, ctDNA demonstrated heightened sensitivity and a more precise correlation with patient progression in comparison to NLR. In the case of gastric cancer, ctDNA values remained positive, whereas NLR exhibited one normal value, suggesting that ctDNA possesses a superior capacity to detect disease persistence. Consequently, ctDNA may serve as a pivotal instrument in the surveillance and customization of oncological treatments, transcending the constraints of conventional inflammatory markers.

No. of Downloads :

0